RU2017119403A3 - - Google Patents

Download PDF

Info

Publication number
RU2017119403A3
RU2017119403A3 RU2017119403A RU2017119403A RU2017119403A3 RU 2017119403 A3 RU2017119403 A3 RU 2017119403A3 RU 2017119403 A RU2017119403 A RU 2017119403A RU 2017119403 A RU2017119403 A RU 2017119403A RU 2017119403 A3 RU2017119403 A3 RU 2017119403A3
Authority
RU
Russia
Application number
RU2017119403A
Other languages
Russian (ru)
Other versions
RU2017119403A (ru
RU2705274C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017119403A publication Critical patent/RU2017119403A/ru
Publication of RU2017119403A3 publication Critical patent/RU2017119403A3/ru
Application granted granted Critical
Publication of RU2705274C2 publication Critical patent/RU2705274C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
RU2017119403A 2014-11-05 2015-11-05 Способы получения двуцепочечных белков в бактериях RU2705274C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462075792P 2014-11-05 2014-11-05
US62/075,792 2014-11-05
US201562207882P 2015-08-20 2015-08-20
US62/207,882 2015-08-20
PCT/US2015/059339 WO2016073791A1 (en) 2014-11-05 2015-11-05 Methods of producing two chain proteins in bacteria

Publications (3)

Publication Number Publication Date
RU2017119403A RU2017119403A (ru) 2018-12-05
RU2017119403A3 true RU2017119403A3 (enExample) 2019-03-27
RU2705274C2 RU2705274C2 (ru) 2019-11-06

Family

ID=54754738

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017119403A RU2705274C2 (ru) 2014-11-05 2015-11-05 Способы получения двуцепочечных белков в бактериях

Country Status (12)

Country Link
US (2) US10112994B2 (enExample)
EP (1) EP3215526A1 (enExample)
JP (3) JP6875276B2 (enExample)
KR (1) KR102709593B1 (enExample)
CN (1) CN108064308B (enExample)
AU (1) AU2015342961B2 (enExample)
BR (1) BR112017009152A2 (enExample)
CA (1) CA2966558C (enExample)
IL (1) IL252027B (enExample)
MX (1) MX384534B (enExample)
RU (1) RU2705274C2 (enExample)
WO (1) WO2016073791A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10112994B2 (en) 2014-11-05 2018-10-30 Genentech, Inc. Methods of producing two chain proteins in bacteria
ES2819256T3 (es) 2014-11-05 2021-04-15 Genentech Inc Métodos para producir proteínas bicatenarias en bacterias
AU2019375413A1 (en) 2018-11-05 2021-05-27 Genentech, Inc. Methods of producing two chain proteins in prokaryotic host cells
CN120248098A (zh) * 2019-01-23 2025-07-04 豪夫迈·罗氏有限公司 在真核宿主细胞中产生多聚体蛋白质的方法
IL317083A (en) 2022-06-17 2025-01-01 Apogee Biologics Inc Antibodies that bind interleukin 13 and methods of use

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE266710C (enExample)
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
EP0308936B1 (en) 1987-09-23 1994-07-06 Bristol-Myers Squibb Company Antibody heteroconjugates for the killing of HIV-infected cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE419355T1 (de) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
JPH08500017A (ja) 1992-08-17 1996-01-09 ジェネンテク，インコーポレイテッド 二特異的免疫アドヘジン
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2364997A3 (en) 1999-01-15 2012-07-04 Genentech, Inc. Polypeptide variants with altered effector function
JP2002541073A (ja) 1999-03-17 2002-12-03 メディカル リサーチ カウンシル Ｉｇドメイン含有ポリペプチドの分子リフォールディング方法
GB9911569D0 (en) * 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
IL149809A0 (en) 1999-12-15 2002-11-10 Genentech Inc Shotgun scanning, a combinatorial method for mapping functional protein epitopes
EP1332222B1 (en) * 2000-11-03 2009-03-25 Genentech, Inc. Metabolic rate shifts in fermentations expressing recombinant proteins
JP4309656B2 (ja) 2000-12-14 2009-08-05 ジェネンテック・インコーポレーテッド 原核生物で生成させた抗体とその用途
CA2454731C (en) 2001-08-27 2010-11-02 Genentech, Inc. A system for antibody expression and assembly
CA2457652C (en) 2001-08-31 2012-08-07 Avidex Limited Soluble t cell receptor
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
KR20130001318A (ko) * 2002-07-19 2013-01-03 애보트 바이오테크놀로지 리미티드 ＴＮＦα 관련 질환의 치료
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7608429B2 (en) 2002-10-31 2009-10-27 Genentech, Inc. Methods and compositions for increasing antibody production
PL212899B1 (pl) 2002-12-16 2012-12-31 Genentech Inc Humanizowane przeciwcialo, kompozycja zawierajaca to przeciwcialo, wyrób fabryczny, przeciwcialo lub jego fragment do zastosowania w sposobie indukowania apoptozy, izolowany kwas nukleinowy, wektor ekspresji, komórka gospodarza, sposób wytwarzania przeciwciala lub jego fragmentu, plynny preparat i zastosowanie przeciwciala do wytwarzania leku
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
WO2004106381A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
CA2530284A1 (en) 2003-07-08 2005-02-03 Genentech, Inc. Il-17 a/f heterologous polypeptides and therapeutic uses thereof
CA2544532C (en) 2003-11-28 2015-06-16 Micromet Ag Compositions comprising polypeptides
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
HRP20120376T1 (hr) 2003-12-23 2012-05-31 Genentech Nova protutijela protiv il-13 i njihove upotrebe
JP4501451B2 (ja) 2004-02-18 2010-07-14 株式会社豊田自動織機 塗料組成物、塗料組成物を用いた透明性保護膜の製造方法および透明性保護膜を有する有機ガラス
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
EP2067789A1 (en) 2004-04-13 2009-06-10 F. Hoffmann-La Roche Ag Anti-P selectin antibodies
JP2008511337A (ja) 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
US8679490B2 (en) 2005-11-07 2014-03-25 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
JP2009536527A (ja) 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド 最適化されたスキャフォールドを備えた結合ポリペプチド
EP2155783B2 (en) 2007-04-03 2022-10-19 Amgen Research (Munich) GmbH Cross-species-specific cd3-epsilon binding domain
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
JP2011519911A (ja) 2008-05-05 2011-07-14 ノヴィミュンヌ エスア 抗ｉｌ１７ａ／ｉｌ−１７ｆ交差反応抗体及びその使用方法
NZ596711A (en) 2009-05-01 2013-11-29 Dual variable domain immunoglobulins and uses thereof
KR101968766B1 (ko) 2009-11-05 2019-04-12 제넨테크, 인크. 이종 폴리펩티드의 분비를 위한 방법 및 조성물
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
GB201012599D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
CN103492562B (zh) * 2011-02-03 2017-04-05 佐马技术有限公司 用于增强细菌中功能蛋白表达的方法和材料
US9158890B2 (en) 2011-07-27 2015-10-13 At&T Mobility Ii Llc Mobile applications and methods for conveying performance information of a cardiac pacemaker
SI2766397T1 (sl) * 2011-10-11 2018-09-28 F. Hoffmann-La Roche Ag Izboljšano sestavljanje bispecifičnih protiteles
RU2015141529A (ru) * 2013-04-05 2017-05-15 Дженентек, Инк. Антитела и биспецифические антитела к il-4 и их применение
SG11201508642WA (en) 2013-04-19 2015-11-27 Sutro Biopharma Inc Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones
AU2015218631A1 (en) 2014-02-21 2016-08-11 Genentech, Inc. Anti-IL-13/IL-17 bispecific antibodies and uses thereof
ES2819256T3 (es) 2014-11-05 2021-04-15 Genentech Inc Métodos para producir proteínas bicatenarias en bacterias
US10112994B2 (en) 2014-11-05 2018-10-30 Genentech, Inc. Methods of producing two chain proteins in bacteria

Also Published As

Publication number Publication date
US20190112368A1 (en) 2019-04-18
CA2966558A1 (en) 2016-05-12
JP2021119777A (ja) 2021-08-19
HK1255201A1 (zh) 2019-08-09
US10112994B2 (en) 2018-10-30
MX2017005930A (es) 2017-06-30
BR112017009152A2 (pt) 2018-03-06
IL252027B (en) 2021-10-31
EP3215526A1 (en) 2017-09-13
RU2017119403A (ru) 2018-12-05
WO2016073791A1 (en) 2016-05-12
CA2966558C (en) 2024-03-12
RU2705274C2 (ru) 2019-11-06
JP2023088935A (ja) 2023-06-27
AU2015342961A1 (en) 2017-06-15
KR102709593B1 (ko) 2024-09-26
US20160159898A1 (en) 2016-06-09
IL252027A0 (en) 2017-06-29
JP6875276B2 (ja) 2021-05-19
US11299539B2 (en) 2022-04-12
AU2015342961B2 (en) 2021-08-12
CN108064308B (zh) 2023-06-09
JP2018500008A (ja) 2018-01-11
KR20170075793A (ko) 2017-07-03
CN108064308A (zh) 2018-05-22
MX384534B (es) 2025-03-14

Similar Documents

Publication Publication Date Title
BR112016003450A2 (enExample)
BR112016013482A2 (enExample)
BR112016018809A2 (enExample)
BR112016016490A2 (enExample)
BR112016015376A2 (enExample)
BR112016018868A2 (enExample)
BR112016018345A2 (enExample)
BR112016015551A2 (enExample)
BR112015027867A2 (enExample)
BR112016018871A2 (enExample)
BR112016016451A2 (enExample)
BR112016018637A2 (enExample)
BR112016017660A2 (enExample)
BR112016019261A2 (enExample)
BR112016017502A2 (enExample)
BR112016017551A2 (enExample)
BR112016017343A2 (enExample)
BR112016018603A2 (enExample)
BR112016019393A2 (enExample)
BR112016019225A2 (enExample)
BR102015031789A2 (enExample)
BR112016018212A2 (enExample)
BR112016015054A2 (enExample)
BR112016015625A2 (enExample)
BR112016015538A2 (enExample)